Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.

British Journal of Haematology
Alexey V Danilov, Daniel O Persky

Abstract

Greater understanding of the mechanisms involved in the disease progression of haematological malignancies has led to the introduction of novel targeted therapies with reduced toxicity compared with chemotherapy-based regimens, which has expanded the treatment options for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL). Ibrutinib is a first-in-class Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of patients with CLL/SLL or relapsed/refractory MCL. However, next-generation BTK inhibitors have been developed with improved specificity and the potential to reduce the off-target toxicity observed with ibrutinib. Acalabrutinib is a highly selective, next-generation BTK inhibitor, which was granted accelerated approval by the US Food and Drug Administration in 2017 for the treatment of adult patients with MCL who have received at least one prior therapy. In November 2019, it was also granted approval for the treatment of adult patients with CLL/SLL on the basis of two phase 3 clinical trials. This review describes the current understanding of acalabrutinib according to clinical study data for the treatment of MCL and CLL/SLL and shares recommendations ...Continue Reading

References

Aug 8, 1998·Seminars in Immunology·A B SatterthwaiteO N Witte
Mar 5, 2003·Annual Review of Immunology·Nicholas Chiorazzi, Manlio Ferrarini
Jun 16, 2004·European Journal of Cancer Care·A RedaelliC L Pashos
Apr 2, 2005·Nature Reviews. Cancer·Ralf Küppers
Dec 26, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Shruti SharmaWenxia Song
Apr 16, 2010·The New England Journal of Medicine·Georg Lenz, Louis M Staudt
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Lee A HonigbergJoseph J Buggy
Jun 4, 2011·Expert Opinion on Therapeutic Targets·Rudi W HendriksFrank Jt Staal
Mar 28, 2012·International Reviews of Immunology·Joseph J Buggy, Laurence Elias
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ranjana H AdvaniNathan H Fowler
Jun 21, 2013·The New England Journal of Medicine·Michael L WangKristie A Blum
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Jun 3, 2014·The New England Journal of Medicine·John C ByrdUNKNOWN RESONATE Investigators
Jul 22, 2014·British Journal of Haematology·Polina ShindiapinaAlexey V Danilov
Feb 12, 2015·Clinical Pharmacology and Therapeutics·L AlinariK A Blum
Jul 15, 2015·Pharmacology Research & Perspectives·Jan de JongErik Mannaert
Dec 8, 2015·The New England Journal of Medicine·Jan A BurgerUNKNOWN RESONATE-2 Investigators
Dec 8, 2015·The New England Journal of Medicine·John C ByrdRichard R Furman
Dec 31, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Viralkumar PatelVarsha Gandhi
Feb 10, 2017·Journal of Thrombosis and Haemostasis : JTH·J J ShatzelT G DeLoughery
Feb 23, 2017·Blood·Benjamin L LampsonJennifer R Brown
Jul 1, 2017·Haematologica·Abby P DouglasConstantine S Tam
Jul 18, 2017·The Journal of Clinical Investigation·Meixiao LongJohn C Byrd
Sep 9, 2017·The Journal of Pharmacology and Experimental Therapeutics·Tjeerd BarfAllard Kaptein
Sep 28, 2017·The New England Journal of Medicine·Steven Le GouillUNKNOWN LYSA Group
Dec 20, 2017·Blood·Jennifer R Brown
Feb 18, 2018·Best Practice & Research. Clinical Haematology·Johanna C Kluin-Nelemans, Jeanette K Doorduijn

❮ Previous
Next ❯

Citations

Jan 13, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Robert Roskoski
Jan 29, 2021·Current Hematologic Malignancy Reports·Edward NabrinskyPaul B Koller
Jan 28, 2021·Expert Review of Anticancer Therapy·Liana NikolaenkoAlexey V Danilov
Apr 3, 2021·Therapeutic Advances in Hematology·Max J Gordon, Alexey V Danilov
Jun 26, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Max J GordonAlexey V Danilov

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.